PRELIMINARY AGENDA NOW AVAILABLE

The growing acceptance and availability of NIPT, based on next-gen sequencing of cell-free DNA from maternal blood, is having a dramatic impact on prenatal testing.  One result has been the steady decline in the number of women choosing invasive testing, with growing replacement of karyotyping by arrays or in some cases sequencing for analysis of these samples.  For non-invasive testing there has been increased differentiation among the leading test service providers.  There has been a push to expand NIPT use beyond higher-risk pregnancies, as well as extending the range of genetic conditions reported from the tests, but such changes come at a price.  Testing based on isolation of fetal cells from maternal blood would provide an attractive alternative to testing of cell-free DNA, but the commercialization of this approach has faced a range of challenges.  Updated comparisons and examination of these issues, and the implementation of these different approaches, will again make for lively discussion and insight into where this field is headed and ways for researchers, test providers, clinicians and clinics to take these developments into consideration.

Preliminary Agenda


INVASIVELY-OBTAINED SAMPLES

What is the Future for Invasive Prenatal Diagnostics

Ronald J. Wapner, M.D., Director, Reproductive Genetics and Vice Chair, Research, Department of Obstetrics & Gynecology, Columbia University Medical School

Next-Gen Sequencing of Invasively-Obtained Samples for Analysis of Genetic Disorders

Cynthia Morton, Ph.D., William Lambert Richardson Professor of Obstetrics, Gynecology & Reproductive Biology and Professor of Pathology, Harvard Medical School; Director, Cytogenetics, Brigham & Women’s Hospital

Challenges with Reproductive Genetic Counseling for Diagnostic Exome Sequencing

Inga Van den Veyer, M.D., Professor, Maternal-Fetal Medicine & Genetics, Baylor College of Medicine

Knowledge Translation: Innovative Educational Strategies to Facilitate the Clinical Implementation of New Prenatal Molecular Genetic Testing

Valerie Desilets, M.D., Medical Geneticist, Departments of Pediatrics and Obstetrics-Gynecology, University of Sherbrooke

SeraCareLuncheon Presentation: Seraseq™ Aneuploidy Reference Materials for Non-Invasive Prenatal Screening (NIPS)

Russell Garlick, Ph.D., CSO, SeraCare Life Sciences

2nd Speaker to be Announced

PANEL DISCUSSION: Challenges of Genetic Counseling in a Rapidly Changing Testing Landscape

Mary-Frances Garber, Executive Director, New England Regional Genetics Group
Additional panelists to be announced


NIPT

The Economics of NIPT

Aaron Caughey, Ph.D., Associate Dean for Women's Health Research & Policy, Oregon Health & Science University

The Pros and Cons of Extending NIPT for All Pregnancies, Not Just Those at Higher Risk

Joe Leigh Simpson , M.D., Senior Vice President for Research and Global Programs, March of Dimes Foundation

Cell-Free Fetal DNA Screening in a Large Integrated Health Care System

Jeffrey Greenberg, MS, Genetic Screening Program Director, Genetic Services, SC Permanente Medical Group

Advancement of Molecular Diagnostics in the Field of Non-Invasive Prenatal Diagnosis of Single Gene Disorders: Present Experiences and Future Developments

Michael Parks, Ph.D., Developmental Scientist, Regional Genetics, Birmingham Women's NHS Foundation Trust

Beyond Aneuploidy: Prenatal Detection and Interpretation of Copy Number Variants (CNVs) that Cause Brain Disorders

David F. Ledbetter, Ph.D., FACMG, Executive Vice President & CSO, Geisinger Health Systems

 

illumina NEW Implementation of NIPT: A Case Study of Technology Evolution  

Gautam Kollu, Head, Market Development, Reproductive and Genetic Health, Illumina 

 
Premaitha HealthClinical Performance of the IONA® Test (CE-IVD) 

William (Pepper) Denman, Ph.D., CMO, Premaitha Health

Ariosa DiagnosticsHealthcare Economics in a General Screening Population

Sabah Oney, Ph.D., Director, Business Development, Operations, Ariosa Diagnostics, Inc

 

PANEL DISCUSSION: NIPT Sequencing Providers

Sabah Oney, Ph.D., Director, Business Development, Ariosa Diagnostics

Gautam Kollu, Head, Market Development, Reproductive and Genetic Health, Illumina

John Anson, Ph.D., Executive Vice President, R&D, Oxford Gene Technology
Stephen Little, Ph.D., CEO, Premaitha Health
Panelists from Natera and Sequenom to be announced


THE PROMISE AND PROSPECTS FOR FETAL CELLS FROM MATERNAL BLOOD

TRIC: A New Window into the Developing Placenta and Fetal Genome

D. Randall Armant, Ph.D., Professor, Obstetrics and Gynecology, Wayne State University School of Medicine

Targeting Pure Fetal DNA from Circulating Trophoblastic Cells for the Development of Prenatal Noninvasive Diagnostics of Genetic Disorders: Advantages and Technical Aspects

Patrizia Paterlini-Brechot, Ph.D., Cellular and Molecular Biology, University of Paris Descartes

Cell-Based Noninvasive Prenatal Diagnosis I: Recovery of Cells

Steen Kølvraa, M.D., CSO, ARCEDI Biotech ApS

Cell-Based Noninvasive Prenatal Diagnosis II: Analysis of Cells

Arthur L. Beaudet, M.D., Chair, Department of Molecular & Human Genetics, Baylor College of Medicine

NanoVelcro Microchips for Isolation and Characterization of Circulating Fetal Nucleated Cells (CFNCs)

Hsian-Rong Tseng, Ph.D., Professor, Molecular and Medical Pharmacology, University of California, Los Angeles

Silicon BiosystemsRecovery and Analysis of Intact Fetal Cells: Noninvasive Prenatal Diagnosis using the DEPArray

Farideh Bischoff, Ph.D.,  Executive Director, Scientific Affairs, Silicon Biosystems, Inc. 


 


 

BIOMARKERS FOR ASSESSING RISKS FOR MATERNAL HEALTH

Targeted Proteomics in Noninvasive Reproductive Diagnosis and Screening

Yong Zhou, Ph.D., Research Scientist, Hood Lab, Institute for Systems Biology

Biomarkers for Assessing the Risk of Preeclampsia

Wendy Davis, CEO, GestVision, Inc.

Assessing the Risk of Pre-Term Labor

Charles Garvey, Sera Prognostics (invited)


PANEL DISCUSSION: Predicting the Landscape for Prenatal Molecular Diagnostics: The Next Few Years

Arthur L. Beaudet, M.D., Chair, Department of Molecular & Human Genetics, Baylor College of Medicine
David F. Ledbetter, Ph.D., FACMG, Executive Vice President & CSO, Geisinger Health Systems
Cynthia Morton, Ph.D., William Lambert Richardson Professor of Obstetrics, Gynecology & Reproductive Biology and Professor of Pathology, Harvard Medical School; Director, Cytogenetics, Brigham & Women’s Hospital
Ronald J. Wapner, M.D., Director, Reproductive Genetics and Vice Chair, Research, Department of Obstetrics & Gynecology, Columbia University Medical School


Program Advisors

arthur_beaudetArthur Beaudet, M.D., Chair, Department of Molecular & Human Genetics, Baylor College of Medicine

David LedbetterCamera Icon PNDXDavid Ledbetter, Ph.D., FACMG, Executive Vice President and CSO, Geisinger Health System

Joe_SimpsoCamera Icon PNDXJoe Leigh Simpson, M.D., Senior Vice President for Research and Global Programs, March of Dimes Foundation

Subhashini ChandrasekharanSubhashini Chandrasekharan, Ph.D., Research Assistant Professor, Institute for Genome Sciences & Policy, Duke University

Cynthia_MortonCynthia Morton, Ph.D., William Lambert Richardson Professor of Obstetrics, Gynecology & Reproductive Biology and Professor of Pathology, Harvard Medical School; Director, Cytogenetics, Brigham & Women’s Hospital

Ronald_WapnerCamera Icon PNDXRonald J. Wapner, M.D., Director, Reproductive Genetics & Vice Chair, Research, Department of Obstetrics & Gynecology, Columbia University Medical Center


For more details on the conference, please contact: 

Phillips Kuhl
President
Cambridge Healthtech Institute
Phone: (+1) 781-972-5410
Email: pkuhl@healthtech.com 

For partnering and sponsorship information, please contact: 

Ilana Quigley
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5457
Email: iquigley@healthtech.com